Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Today, 10:39 AMElanco beats Q3 with EPS $0.27 (+42% YoY), revenue $1.265B (+11% YoY), raises 2026 guidance on pet innovation growth
Index
-
Market Cap
12.91B
Enterprise Value
16.30B
Income
-199.00M
Sales
5.02B
Book/sh
13.19
Cash/sh
1.06
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
9900
IPO
Sep 20, 2018
P/E
-
Forward P/E
20.42
PEG
1.37
P/S
2.57
P/B
1.96
P/C
24.35
P/FCF
34.06
EV/EBITDA
15.88
EV/Sales
3.25
Quick Ratio
1.10
Current Ratio
2.05
Debt/Eq
0.59
LT Debt/Eq
0.58
Option/Short
Yes / Yes
EPS (ttm)
-0.40
EPS next Y
1.27
EPS next Q
0.18
EPS this Y
20.42%
EPS next Y
11.79%
EPS next 5Y
14.89%
EPS past 3/5Y
-43.04% 18.11%
Sales past 3/5Y
2.25% 7.57%
EPS Y/Y TTM
-145.71%
Sales Y/Y TTM
11.95%
EPS Q/Q
380.63%
Sales Q/Q
10.23%
Insider Own
1.02%
Insider Trans
1.37%
Inst Own
114.71%
Inst Trans
4.43%
ROA
-1.46%
ROE
-2.98%
ROIC
-1.91%
Gross Margin
44.28%
Oper. Margin
6.63%
Profit Margin
-3.96%
SMA20
10.73%
SMA50
11.68%
SMA200
8.55%
Trades
Shs Outstand
499.55M
Shs Float
494.51M
52W High
27.98 -7.67%
52W Low
19.40 33.17%
Volatility
4.11% 3.19%
ATR (14)
0.92
RSI (14)
65.53
Beta
1.69
Rel Volume
1.68
Avg Volume
6.04M
Volume
5,517,056
Perf Week
12.03%
Perf Month
14.62%
Perf Quarter
15.96%
Perf Half Y
9.24%
Perf YTD
14.16%
Perf Year
20.05%
Perf 3Y
176.01%
Perf 5Y
-24.22%
Perf 10Y
-
Prev Close
23.68
Price
25.83
Change %
9.10%
Consensus
Strong Buy
Avg. Price Target
$30.42
Implied Upside
+17.7%
Analysts14incl. previous ratings
Rating Distribution12 Buy · 2 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Oct 20, 2026Downgrade
JEF logoJJefferies
Buy → Hold$24-7.1%
Oct 16, 2026Initiated
GS logoGGoldman
Buy$32+23.9%
Apr 15, 2026Initiated
C logoCCitigroup
Buy$30+16.1%
Jan 22, 2026Upgrade
PPiper Sandler
Neutral → Overweight
Dec 09, 2025Initiated
BCS logoBBarclays
Overweight$30+16.1%
Nov 21, 2025Initiated
KEY logoKKeyBanc Capital Markets
Overweight$27+4.5%
Nov 19, 2025Upgrade
AArgus
Hold → Buy$25-3.2%
Oct 07, 2025Upgrade
JPM logoJJP Morgan
Neutral → Overweight$24-7.1%
Jul 17, 2025Upgrade
LLeerink Partners
Market Perform → Outperform$18-30.3%
Jun 26, 2025Upgrade
WWilliam Blair
Mkt Perform → Outperform
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bettington Timothy JSEE REMARKSOct 15 '26Sale23.004,350100,050138,911Oct 19 04:15 PM
Bettington Timothy JOfficerOct 15 '26Proposed Sale23.004,350100,050Oct 15 04:01 PM
Kurzius Lawrence ErikDirectorAug 20 '26Buy23.4040,000935,920188,647Aug 21 04:16 PM
O'Neill ShivGC AND CORP SECAug 18 '26Buy23.583,99894,27387,832Aug 18 04:32 PM
Harrington Michael JDirectorAug 12 '26Buy21.825,000109,100131,451Aug 13 04:28 PM
VanHimbergen Robert MEVP and CFOAug 07 '26Buy23.084,20096,926137,516Aug 10 04:14 PM
Herendeen PaulDirectorAug 07 '26Buy23.6810,000236,850111,687Aug 10 04:13 PM
Modi Rajeev A.SEE REMARKSMay 15 '26Buy20.354,91199,939160,812May 19 04:39 PM
Simmons Jeffrey NPRESIDENT, CEO AND DIRECTORMay 15 '26Buy20.094,97199,843171,971May 19 04:38 PM
Kurzius Lawrence ErikDirectorDec 12 '25Buy21.3010,000213,000131,773Dec 16 04:42 PM
Modi Rajeev A.SEE REMARKSDec 11 '25Buy21.334,50095,985123,082Dec 15 04:43 PM
VanHimbergen Robert MEVP and CFODec 11 '25Buy21.646,950150,426124,233Dec 15 04:42 PM
Simmons Jeffrey NPRESIDENT, CEO AND DIRECTORDec 11 '25Buy21.7522,000478,496167,000Dec 15 04:41 PM
Elanco Animal Health, Inc. develops, manufactures, and markets products for pets and farm animals. Its products include Advantage Family, Atopica, Credelio Family, Drontal Family, Galliprant, Interceptor Plus, Milbemax, Onsior, Seresto, Trifexis, TruCan, AviPro, Baytril, Catosal, Denagard, and Experior. The company was founded in 1954 and is headquartered in Indianapolis, IN.
PresidentMr. Jeffrey N. Simmons
Executive VP & CFOMr. Robert M. VanHimbergen
Executive VP & President of Elanco InternationalDr. Ramiro Martin Cabral
Executive Vice President of ResearchDr. Ellen de Brabander Ph.D.
Executive Vice President of Center of Strategic GrowthMr. Timothy J. Bettington